يعرض 1 - 2 نتائج من 2 نتيجة بحث عن '"Zuzana Machackova"', وقت الاستعلام: 0.75s تنقيح النتائج
  1. 1
    Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study

    المؤلفون: Joyce O'Shaughnessy, Susana Sousa, Josefina Cruz, Lesley Fallowfield, Päivi Auvinen, Catarina Pulido, Ana Cvetanovic, Sharon Wilks, Leonor Ribeiro, Mauricio Burotto, Dirk Klingbiel, Dimitri Messeri, Ari Alexandrou, Peter Trask, Judy Fredriksson, Zuzana Machackova, Ljiljana Stamatovic, Ernesto Korbenfeld, Jorge Nadal, Helio Pinczowski, Felipe J. Cruz, Gustavo Sousa, Aline C. Goncalves, Gisah Guilgen, Antti Jekunen, Winne Yeo, Chi K. Cheng, Hikmat A. Razeq, Fadi Karak, Fadi Farhat, Servando C. Huerta, Brizio M. Jaime, Juan Feregrino, Omar Castillo-Fernandez, Juan C. Alcedo, Maria Dionisio, Salha Bujassoum, Hatoon Bakhraibah, Alvaro R. Lescure, Camilla Wendt, Sara Margolin, Helena G. Björneklett, Michelina Cairo, Shaker Dakhil, Nguyet Le-Lindqwister, Ling Ma, Kristi J. McIntyre, Joyce O’Shaughnessy, Svetislava J. Vukelja, Donald Richards, John Wallmark

    مصطلحات موضوعية: 0301 basic medicine, Cancer Research, Receptor, ErbB-2, Phases of clinical research, Gastroenterology, Subcutaneous injection, 0302 clinical medicine, Trastuzumab, Antineoplastic Combined Chemotherapy Protocols, Infusions, Intravenous, Adjuvant, Early breast cancer, Aged, 80 and over, Patient preference, Cross-Over Studies, Subcutaneous, Patient Preference, Fixed dose, Middle Aged, Neoadjuvant Therapy, Drug Combinations, Oncology, Chemotherapy, Adjuvant, Patient Satisfaction, 030220 oncology & carcinogenesis, Female, Pertuzumab, medicine.drug, Adult, Quality of life, medicine.medical_specialty, Injections, Subcutaneous, Fixed-dose combination, Breast Neoplasms, Antibodies, Monoclonal, Humanized, 03 medical and health sciences, Young Adult, Healthcare resource, Internal medicine, medicine, Humans, Adverse effect, Aged, Neoplasm Staging, Patient-reported outcomes, business.industry, Confidence interval, 030104 developmental biology, business

    وصف الملف: application/pdf

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efa4c6a666e370a233289e49fa120291
    https://zenodo.org/record/5196150

    View record from ScienceDirect Full Text via ClinicalKey
    أضف إلى المفضلة
  2. 2
    Describing U.S. real-world patients (pts) with hormone receptor-positive early breast cancer (HR+ EBC) by risk status

    المؤلفون: Mary K. Downer, Amin Yakubu, Pablo Diego Pérez-Moreno, Anna Steenrod, Tanja Badovinac Crnjevic, Zuzana Machackova

    المصدر: Journal of Clinical Oncology. 40:e12548-e12548

    مصطلحات موضوعية: Cancer Research, Oncology

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::63b414fedd59edb8d0fa713550727bb8
    https://doi.org/10.1200/jco.2022.40.16_suppl.e12548

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء